Skip to main content
Lavipharm S.A. logo

Lavipharm S.A. — Investor Relations & Filings

Ticker · LAVI ISIN · GRS246003008 LEI · 213800USC69CRPRGWJ15 AT Manufacturing
Open in API
Filings indexed 42 across all filing types
Latest filing 2025-07-10 Share Issue/Capital Cha…
Country GR Greece
Listing AT LAVI

About Lavipharm S.A.

https://lavipharm.com/

Lavipharm S.A. is an integrated healthcare company engaged in the research, development, manufacturing, marketing, and distribution of pharmaceutical products. Established in 1911, the company offers a diverse portfolio that includes prescription (Rx) and over-the-counter (OTC) medicines, as well as food supplements. A key area of innovation for the company is its development of transdermal drug delivery systems. Lavipharm focuses on providing treatment options across several major therapeutic areas, including cardiology, neurology (Central Nervous System), urology, oncology, and chronic pain management.

Recent filings

Filing Released Lang Actions
Έντυπο παροχής πληροφοριών Κανονισμού (ΕΕ) 2017/1129 (άρθρ. 1 παρ. 5 η’) αναφορικά με την Εισαγωγή για Διαπραγμάτευση Νέων Κοινών Ονομαστικών Μετοχών
Share Issue/Capital Change Classification · 98% confidence The document is titled "Έντυπο παροχής πληροφοριών Κανονισμού (ΕΕ) 2017/1129" (Information Document pursuant to Regulation (EU) 2017/1129) concerning the admission to trading of New Common Shares. It details a capital increase resulting from a Stock Award Plan for senior management, involving the issuance of 352,524 new shares. This action directly relates to changes in the company's capital structure and share issuance, specifically for employee/management compensation and subsequent listing. This aligns best with the 'Share Issue/Capital Change' category (SHA), as the core event is the issuance of new shares following a capital increase decision by the General Assembly. While it involves management compensation, the primary regulatory action described is the capital change and subsequent admission to trading.
2025-07-10 Greek (modern)
Έντυπο παροχής πληροφοριών Κανονισμού (ΕΕ) 2017/1129 (άρθρ. 1 παρ. 4 θ΄) αναφορικά με την Διάθεση Νέων Κοινών Ονομαστικών Μετοχών
Share Issue/Capital Change Classification · 98% confidence The document is titled "Έντυπο παροχής πληροφοριών Κανονισμού (ΕΕ) 2017/1129... αναφορικά με την Διάθεση Νέων Κοινών Ονομαστικών Μετοχών της Εταιρείας... LAVIPHARM A.E." (Information Document pursuant to Regulation (EU) 2017/1129... regarding the Allotment of New Common Registered Shares of the Company...). The text explicitly details the free allotment of 352,524 new shares to senior executives as part of a Stock Award Plan, following decisions made by the Extraordinary and Regular General Meetings. This action involves the issuance of new shares and a corresponding capital increase. This falls directly under the definition of 'Share Issue/Capital Change' (SHA), which covers announcements regarding new share issues or capital structure changes. It is not a general earnings release (ER), a full annual report (10-K), or just a notice of dividend (DIV).
2025-07-09 Greek (modern)
ΓΝΩΣΤΟΠΟΙΗΣΗ ΑΠΟΚΟΠΗΣ ΔΙΚΑΙΩΜΑΤΟΣ ΜΕΡΙΣΜΑΤΟΣ / ΠΛΗΡΩΜΗΣ ΜΕΡΙΣΜΑΤΟΣ/ ΠΡΟΜΕΡΙΣΜΑΤΟΣ
Notice of Dividend Amount Classification · 99% confidence The document is an official announcement dated July 3, 2025, detailing the distribution of a dividend ('ΔΙΑΝΟΜΗ ΜΕΡΙΣΜΑΤΟΣ') approved by the Annual General Meeting. It specifies the total amount, the amount per share (€0.02 gross, €0.019 net), the Record Date (July 18, 2025), the Ex-Dividend Date (July 17, 2025), and the payment date (July 24, 2025). This content directly corresponds to the definition of a Notice of Dividend Amount (DIV). Although it references the AGM approval, the primary subject is the dividend payment mechanics, not the AGM materials themselves (AGM-R) or the general earnings release (ER).
2025-07-03 Greek (modern)
ΔΕΛΤΙΟ ΤΥΠΟΥ ΓΕΝΙΚΗΣ ΣΥΝΕΛΕΥΣΗΣ
AGM Information Classification · 99% confidence The document text is titled with the Greek equivalent of 'Annual General Meeting of Shareholders of Lavipharm A.E.' and details the proceedings, including the election of a new Chairman of the Board, discussions on business performance, the announcement of a dividend distribution, and the approval of various corporate governance items (like the Audit Committee re-election and changes to the articles of association related to a Stock Award Plan). These elements—shareholder meeting proceedings, board changes discussed in the context of the meeting, and dividend approval—are central to an Annual General Meeting (AGM). Therefore, the document is classified as AGM Information (AGM-R). The length (5382 chars) is substantial, indicating it is the content of the meeting itself, not just a brief announcement of the meeting.
2025-07-03 Greek (modern)
PRESS RELEASE
AGM Information Classification · 99% confidence The document explicitly details events, discussions, and outcomes from the 'Annual General Meeting of Shareholders' (AGM). Key indicators include the mention of the AGM, the election of a new Chair of the Board (Ms. Sofia Kounenaki-Efraimoglou), the announcement of the first dividend distribution, and the approval of agenda items like the Remuneration Policy and the re-election of the Audit Committee. This content perfectly aligns with the definition of AGM Information.
2025-07-03 English
ΑΝΑΚΟΙΝΩΣΗ ΕΠΙΤΡΟΠΗΣ ΕΛΕΓΧΟΥ
AGM Information Classification · 99% confidence The document text is a formal announcement ('ΑΝΑΚΟΙΝΩΣΗ') detailing decisions made during the Annual General Meeting ('Τακτική Γενική Συνέλευση των Μετόχων') held on July 3, 2025. Specifically, it concerns the election and composition of the Audit Committee ('Επιτροπή Ελέγχου') and references relevant Greek corporate governance laws (ν. 4449/2017, ν. 4706/2020). Since the content is directly related to the proceedings and outcomes of the AGM, the most appropriate classification is AGM Information (AGM-R). It is not a general regulatory filing (RNS) because it is highly specific to the AGM's decisions.
2025-07-03 Greek (modern)

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.